Literature DB >> 11773088

Comparison of two culture methods for detection of tobramycin-resistant gram-negative organisms in the sputum of patients with cystic fibrosis.

Jill M Van Dalfsen1, Jenny R Stapp, Charles Phelps, Patricia Stewart, Jane L Burns.   

Abstract

A culture method utilizing quantitative plating on antibiotic-containing media has been proposed as a technique for the detection of tobramycin-resistant organisms that is more sensitive than standard methods. Typical sputum culture methods quantitate the relative amounts of each distinct morphotype, followed by antibiotic susceptibility testing of a single colony of each morphotype. Sputum specimens from 240 cystic fibrosis patients were homogenized, serially diluted, and processed in parallel by the standard method (MacConkey agar and OF basal medium with agar, polymyxin, bacitracin, and lactose) and by plating on antibiotic-containing media (MacConkey agar with tobramycin added at 25 microg/ml [MAC-25] and 100 microg/ml [MAC-100]). MICs of tobramycin were determined for all Pseudomonas aeruginosa isolates by broth microdilution. Growth of P. aeruginosa on MAC-25 was considered to be equivalent to a tobramycin MIC of > or = 16 microg/ml, and growth on MAC-100 was considered to be equivalent to a tobramycin MIC of > or = 128 microg/ml. Analysis of method-specific detection rates showed that tobramycin-containing medium was more sensitive than the standard method for the detection of tobramycin-resistant P. aeruginosa, Stenotrophomonas maltophilia, and Achromobacter xylosoxidans but was less sensitive for the detection of Burkholderia cepacia than the standard method. When MICs for P. aeruginosa that grew on tobramycin-containing medium were tested by broth microdilution, the MICs for 28 of 121 strains (23%) growing on MAC-25 and 22 of 56 strains (39%) growing on MAC-100 were MICs < 16 and < 128 microg/ml, respectively. Addition of a tobramycin-containing MacConkey plate to the routine media for sputum culture may provide additional, clinically relevant microbiologic data.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11773088      PMCID: PMC120123          DOI: 10.1128/JCM.40.1.26-30.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.

Authors:  J L Burns; J M Van Dalfsen; R M Shawar; K L Otto; R L Garber; J M Quan; A B Montgomery; G M Albers; B W Ramsey; A L Smith
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

2.  Facilitated detection of antibiotic-resistant Pseudomonas in cystic fibrosis sputum using homogenized specimens and antibiotic-containing media.

Authors:  M Maduri-Traczewski; C L'Heureux; L Escalona; A Macone; D Goldmann
Journal:  Diagn Microbiol Infect Dis       Date:  1986-11       Impact factor: 2.803

3.  The effect of sublethal concentrations of aminoglycosides on adherence of Pseudomonas aeruginosa to hamster tracheal epithelium.

Authors:  T A Geers; N R Baker
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

4.  Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis.

Authors:  A L Smith; C Doershuk; D Goldmann; E Gore; B Hilman; M Marks; R Moss; B Ramsey; G Redding; T Rubio; J Williams-Warren; R Wilmott; H D Wilson; R Yogev
Journal:  J Pediatr       Date:  1999-04       Impact factor: 4.406

5.  Serotypes and antibiotic susceptibilities of Pseudomonas aeruginosa isolates from single sputa of cystic fibrosis patients.

Authors:  T W Seale; H Thirkill; M Tarpay; M Flux; O M Rennert
Journal:  J Clin Microbiol       Date:  1979-01       Impact factor: 5.948

6.  Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis.

Authors:  M J Thomassen; C A Demko; B Boxerbaum; R C Stern; P J Kuchenbrod
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

7.  Selective and differential medium for recovery of Pseudomonas cepacia from the respiratory tracts of patients with cystic fibrosis.

Authors:  D F Welch; M J Muszynski; C H Pai; M J Marcon; M M Hribar; P H Gilligan; J M Matsen; P A Ahlin; B C Hilman; S A Chartrand
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

8.  Aminoglycoside-selected subpopulations of Pseudomonas aeruginosa: characterization and virulence in normal and leukopenic mice.

Authors:  A U Gerber; W A Craig
Journal:  J Lab Clin Med       Date:  1982-11

9.  Virulence of Pseudomonas aeruginosa strains with mechanisms of microbial persistence for beta-lactam and aminoglycoside antibiotics in a mouse infection model.

Authors:  L E Bryan; A J Godfrey; T Schollardt
Journal:  Can J Microbiol       Date:  1985-04       Impact factor: 2.419

10.  Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo.

Authors:  F J McLaughlin; W J Matthews; D J Strieder; B Sullivan; A Taneja; P Murphy; D A Goldmann
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

View more
  2 in total

1.  Single-molecule long-read 16S sequencing to characterize the lung microbiome from mechanically ventilated patients with suspected pneumonia.

Authors:  Ian Toma; Marc O Siegel; John Keiser; Anna Yakovleva; Alvin Kim; Lionel Davenport; Joseph Devaney; Eric P Hoffman; Rami Alsubail; Keith A Crandall; Eduardo Castro-Nallar; Marcos Pérez-Losada; Sarah K Hilton; Lakhmir S Chawla; Timothy A McCaffrey; Gary L Simon
Journal:  J Clin Microbiol       Date:  2014-08-20       Impact factor: 5.948

2.  Utility of gram staining for evaluation of the quality of cystic fibrosis sputum samples.

Authors:  Bindu Nair; Jenny Stapp; Lynn Stapp; Linda Bugni; Jill Van Dalfsen; Jane L Burns
Journal:  J Clin Microbiol       Date:  2002-08       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.